Payment overview · 2025
General Payments
$344.72
17 reported records · 10 companies
Healthcare provider profile · identity verified
John Allen Cockerell, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NORTH LITTLE ROCK, AR · NPI 1669867099
Verified facts
What the public records show
CMS Open Payments records show John Allen Cockerell, M.D. received $344.72 in general payments during 2025 across 17 reported records.
Astellas Pharma US Inc accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $92.84 | 26.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $79.15 | 23.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.15 | 9.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.36 | 9.1% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.40 | 8.2% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $17.43 | 5.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.82 | 4.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.79 | 4.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.04 | 4.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.74 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $344.72 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $92.84 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $46.27 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.88 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.15 | 2 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $31.36 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.36 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $28.40 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 328 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 260 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 236 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 194 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 193 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 161 | 55 |
| Gabapentin | Gabapentin | 148 | 36 |
| Lisinopril | Lisinopril | 148 | 44 |
| Omeprazole | Omeprazole | 148 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 43 |
| Tramadol Hcl | Tramadol Hcl | 138 | 30 |
| Trazodone Hcl | Trazodone Hcl | 138 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 35 |
| Clonazepam | Clonazepam | 121 | 24 |
| Metformin Hcl | Metformin Hcl | 119 | 33 |
| Furosemide | Furosemide | 118 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 27 |
| Prednisone | Prednisone | 114 | 68 |
| Meloxicam | Meloxicam | 108 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 103 | 25 |
| Alprazolam | Alprazolam | 98 | 18 |
| Famotidine | Famotidine | 97 | 32 |
| Nifedipine Er | Nifedipine | 96 | 25 |
| Simvastatin | Simvastatin | 96 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 24 |
| Losartan Potassium | Losartan Potassium | 94 | 26 |
| Etodolac | Etodolac | 92 | 19 |
| Ozempic | Semaglutide | 90 | 15 |
| Metformin Hcl Er | Metformin Hcl | 89 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 82 | 18 |
| Montelukast Sodium | Montelukast Sodium | 80 | 16 |
| Sertraline Hcl | Sertraline Hcl | 80 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 31 |
| Baclofen | Baclofen | 79 | 28 |
| Glipizide Er | Glipizide | 79 | 16 |
| Diazepam | Diazepam | 75 | 11 |
| Mounjaro | Tirzepatide | 74 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 73 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 72 | suppressed |
| Jardiance | Empagliflozin | 71 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 70 | 19 |
| Bupropion Xl | Bupropion Hcl | 67 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 53 |
| Valsartan | Valsartan | 62 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 16 |
| Eliquis | Apixaban | 60 | 12 |
| Ondansetron Odt | Ondansetron | 60 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 15 |
| Allopurinol | Allopurinol | 57 | 14 |
| Atenolol | Atenolol | 55 | 14 |
| Potassium Chloride | Potassium Chloride | 54 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 13 |
| Azithromycin | Azithromycin | 52 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 27 |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 12 |
| Methocarbamol | Methocarbamol | 48 | 14 |
| Propranolol Hcl | Propranolol Hcl | 48 | 12 |
| Nabumetone | Nabumetone | 47 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Carvedilol | Carvedilol | 44 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 43 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 19 |
| Estradiol | Estradiol | 41 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 29 | 22 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 20 |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 20 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 15 |
| Glipizide | Glipizide | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 14 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Epinephrine | Epinephrine | 14 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 14 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Cimetidine | Cimetidine | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $344.72 · 17 records | Astellas Pharma US Inc | AIRSUPRA, Cologuard Collection Kit, FREESTYLE LIBRE 3, QULIPTA, Qelbree, Saxenda, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XYOSTED | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error